<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038881</url>
  </required_header>
  <id_info>
    <org_study_id>POX-MVA-037</org_study_id>
    <nct_id>NCT02038881</nct_id>
  </id_info>
  <brief_title>Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection</brief_title>
  <official_title>Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bavarian Nordic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this clinical trial is to generate additional safety data in a highly
      immunocompromised population. HIV-infected persons are considered excellent candidates to
      represent the highly immunocompromised population for enrolment in this trial. Additionally,
      the immune system's response (protection against smallpox as measured by the amount of
      antibodies produced) following injections of MVA-BN® smallpox vaccine will be evaluated. All
      participants in this trial will be randomly and evenly assigned to one of three groups to
      receive two, three or four injections. Group 1 will receive the standard regime consisting of
      one dose at each vaccination time point, Group 2 will receive two doses at each vaccination
      time point and Group 3 will receive a booster vaccination 12 weeks after the standard
      vaccination schedule with MVA-BN® smallpox vaccine. Participation in the trial is scheduled
      to last up to 75 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 28, 2014</start_date>
  <completion_date type="Actual">May 10, 2017</completion_date>
  <primary_completion_date type="Actual">May 10, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With SAEs</measure>
    <time_frame>within 75 weeks</time_frame>
    <description>Occurrence, relationship and intensity of any serious AE (SAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With AESIs</measure>
    <time_frame>within 75 weeks</time_frame>
    <description>Occurrence, relationship to the trial vaccine, and intensity of any adverse event of special interest (AESI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Related Grade &gt;=3 Adverse Events</measure>
    <time_frame>within 29 days after any vaccination</time_frame>
    <description>Number of Participants with any Grade &gt;=3 Adverse Event probably, possibly, or definitely related to the study vaccine. Pooled solicited and unsolicited AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Unsolicited Non-serious Adverse Events: Relationship to Vaccination</measure>
    <time_frame>within 29 days after any vaccination</time_frame>
    <description>Occurrence of unsolicited non-serious AEs by relationship to study vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Unsolicited Non-serious Adverse Events: Intensity</measure>
    <time_frame>within 29 days after any vaccination</time_frame>
    <description>Occurrence of unsolicited non-serious AEs by Intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited Local Adverse Events</measure>
    <time_frame>within 8 days after any vaccination</time_frame>
    <description>Number of participants with solicited local AEs (redness, swelling, induration, pruritus, and pain) by intensity. Percentages based on subjects with at least one completed diary card. [Injection site erythema, injection site swelling and injection site induration--all sizes measured in diameter with max severity of: 0=0, 1 = &lt;30 mm, 2 = ≥30 - &lt;100 mm, 3 = ≥100 mm. Injection site pruritus: 0=absent, 1=mild, 2=moderate, 3=severe. Injection site pain: 0=absent, 1=painful to touch, 2=painful when limb is moved, 3=spontaneously painful/prevents normal activity.]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited General AEs</measure>
    <time_frame>within 8 days after any vaccination</time_frame>
    <description>Number of Participants with solicited systemic/general AEs (pyrexia, headache, myalgia, nausea, fatigue, and chills) by intensity. Percentages based on subjects with at least one completed diary card. [Body temperature: 0 = &lt;99.5 F (&lt;37.5 C), 1 = ≥99.5 - &lt;100.4 F (≥37.5 - &lt;38.0 C), 2= ≥100.4 - &lt;102.2 F (≥38.0 - &lt;39.0 C), 3= ≥102.2 - &lt;104.0 F (≥39.0 - &lt;40.0 C), 4= ≥ 104.0 F (≥40.0 C); pyrexia is defined as oral temperature ≥ 100.4 F (≥ 38.0 C).] [Headache, myalgia, nausea, chills and fatigue: 0 = none, 1 = mild: easily tolerated, minimal discomfort and no interference with daily activity, 2 = moderate: some interference with daily activity, 3 = severe: prevents daily activity.]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T Cell Counts</measure>
    <time_frame>within 15 days after each vaccination</time_frame>
    <description>Mean CD4+ T-cell counts over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMT) Measured by Enzyme-linked Immunosorbent Assay (ELISA) at All Immunogenicity Sampling Points</measure>
    <time_frame>within 64 weeks</time_frame>
    <description>GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA GMT 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined))</measure>
    <time_frame>Week 6</time_frame>
    <description>GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA GMT 2 Weeks Following the Last Vaccination</measure>
    <time_frame>Week 6 (Groups 1 and 2), Week 14 (Group 3)</time_frame>
    <description>GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA GMT During Follow-up</measure>
    <time_frame>Weeks 30 and 56 (Groups 1 and 2), Weeks 38 and 64 (Group 3)</time_frame>
    <description>GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'. Participants discontinued prior to the follow-up visits are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs Measured by Plaque Reduction Neutralization Test (PRNT) at All Immunogenicity Sampling Points</measure>
    <time_frame>within 64 weeks</time_frame>
    <description>GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRNT GMT 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined))</measure>
    <time_frame>Week 6</time_frame>
    <description>GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRNT GMT 2 Weeks Following the Last Vaccination</measure>
    <time_frame>Week 6 (Groups 1 and 2), Week 14 (Group 3)</time_frame>
    <description>GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRNT GMT During Follow-up</measure>
    <time_frame>Weeks 30 and 56 (Groups 1 and 2), Weeks 38 and 64 (Group 3)</time_frame>
    <description>GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'. Participants discontinued prior to the follow-up visits are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion by ELISA</measure>
    <time_frame>within 64 weeks</time_frame>
    <description>SC rate based on ELISA. SC is defined as the appearance of antibody titers &gt;= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion by ELISA 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined))</measure>
    <time_frame>Week 6</time_frame>
    <description>SC rate based on ELISA. SC is defined as the appearance of antibody titers &gt;= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion by ELISA 2 Weeks Following the Last Vaccination</measure>
    <time_frame>Week 6 (Groups 1 and 2), Week 14 (Group 3)</time_frame>
    <description>SC rate based on ELISA. SC is defined as the appearance of antibody titers &gt;= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion by ELISA During Follow-up</measure>
    <time_frame>Weeks 30 and 56 (Groups 1 and 2), Weeks 38 and 64 (Group 3)</time_frame>
    <description>SC rate based on ELISA. SC is defined as the appearance of antibody titers &gt;= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion by PRNT</measure>
    <time_frame>within 64 weeks</time_frame>
    <description>SC rate based on PRNT. SC is defined as the appearance of antibody titers &gt;= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion by PRNT 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined))</measure>
    <time_frame>Week 6</time_frame>
    <description>SC rate based on PRNT. SC is defined as the appearance of antibody titers &gt;= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion by PRNT 2 Weeks Following the Last Vaccination</measure>
    <time_frame>Week 6 (Groups 1 and 2), Week 14 (Group 3)</time_frame>
    <description>SC rate based on PRNT. SC is defined as the appearance of antibody titers &gt;= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion by PRNT During Follow-up</measure>
    <time_frame>Weeks 30 and 56 (Groups 1 and 2), Weeks 38 and 64 (Group 3)</time_frame>
    <description>SC rate based on PRNT. SC is defined as the appearance of antibody titers &gt;= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Smallpox</condition>
  <arm_group>
    <arm_group_label>Group 1 (standard regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (double dose regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (booster regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMVAMUNE®</intervention_name>
    <description>0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
    <arm_group_label>Group 1 (standard regimen)</arm_group_label>
    <arm_group_label>Group 2 (double dose regimen)</arm_group_label>
    <arm_group_label>Group 3 (booster regimen)</arm_group_label>
    <other_name>IMVANEX®</other_name>
    <other_name>MVA-BN® smallpox vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects aged between 18-45 years, vaccinia-naïve.

          2. HIV-1 infection documented by ELISA and confirmed by Western blot at any time prior to
             study entry. HIV-1 deoxyribonucleic acid (DNA) polymerase chain reaction (PCR), HIV-1
             culture, HIV-1 antigen, plasma HIV-1 ribonucleic acid (RNA), or a second antibody test
             other than ELISA is acceptable as an alternative test at any time prior to study
             entry.

          3. On stable antiretroviral therapy (ART) i.e. Combination ART for at least 6 months.
             Subject must be on the same ART regimen for at least 12 weeks with no change prior to
             enrollment in this clinical trial.

          4. Screening HIV-1 RNA &lt; 200 copies/ml by US Food and Drug Administration (FDA) approved
             PCR assay within 45 days prior to study entry.

          5. Current CD4 counts ≥ 100 cells/µl ≤ 500 cells/µl.

          6. Documented nadir CD4 count &lt; 200 cells/µl at any time prior to enrollment.

          7. Hemoglobin ≥ 9.0 g/dl for female subjects, ≥ 10.0 g/dl or male subjects.

          8. Platelets ≥ 100,000/mm3.

          9. Ability and willingness of subject to provide written informed consent.

         10. Body Mass Index (BMI) ≥ 18.5 and &lt; 35 kg/m2.

         11. Women of childbearing potential (WOCBP) must have used an acceptable method of
             contraception for 30 days prior to the first vaccination, must agree to use an
             acceptable method of contraception during the trial, and must avoid becoming pregnant
             for at least 28 days after the last vaccination. A woman is considered of childbearing
             potential unless post-menopausal (defined as ≥ 12 months without a menstrual period)
             or surgically sterilized. Acceptable contraception methods are restricted to
             abstinence, barrier contraceptives, intrauterine contraceptive devices or licensed
             hormonal products).

         12. WOCBP must have a negative serum pregnancy test at screening (SCR) and a negative
             urine pregnancy test within 24 hours prior to each vaccination.

         13. Absolute neutrophil count cells ≥ 750/mm3.

         14. Adequate renal function defined as a calculated Creatinine Clearance (CrCl) &gt; 60
             ml/min as estimated by the Cockcroft-Gault equation.

               1. For men: (140 - age in years) x (body weight in kg) ÷ (serum creatinine in mg/dl
                  x 72) = CrCl (ml/min)

               2. For women: multiply the result by 0.85 = CrCl (ml/min).Adequate hepatic function
                  defined as: Total bilirubin ≤ 2 x upper limit normal (ULN) in the absence of
                  other evidence of significant liver disease

         15. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline
             phosphatase ≤ 2.5 x ULN.

         16. Troponin I &lt; 2 x ULN at entry in the clinical trial.

         17. Electrocardiogram (ECG) without clinically significant findings (e.g. any kind of
             atrioventricular or intraventricular conditions or blocks such as complete left or
             right bundle branch block, AV node block, QTc or PR prolongation, premature atrial
             contractions or other atrial arrhythmia, sustained ventricular arrhythmia, two
             premature ventricular contractions (PVC) in a row, ST elevation consistent with
             ischemia).

        Exclusion Criteria:

          1. Pregnant or breast-feeding women.

          2. Typical vaccinia scar.

          3. Known or suspected history of smallpox vaccination.

          4. History of vaccination with any poxvirus-based vaccine.

          5. Uncontrolled serious infection, i.e. not responding to antimicrobial therapy.

          6. History of any serious medical condition, which in the opinion of the investigator
             would compromise the safety of the subject or would limit the subject's ability to
             complete the trial including uncontrolled diabetes as according to the 'Division of
             Acquired Immune Deficiency Syndrome (AIDS) Table for Grading the Severity of Adult and
             Pediatric Adverse Events' Version 1.0, December 2004, Clarification August 2009.

          7. History of or active autoimmune disease, persons with vitiligo or thyroid disease
             taking thyroid replacement are not excluded.

          8. Known or suspected impairment of immunologic function except those defined in the
             inclusion criteria, including, but not limited to clinically significant liver
             disease, diabetes mellitus type I and moderate to severe kidney impairment.

          9. History of malignancy other than squamous cell or basal cell skin cancer, unless there
             has been surgical excision that is considered to have achieved cure. Subjects with
             history of skin cancer must not be vaccinated at the previous tumor site.

         10. History or clinical manifestation of clinically significant and severe hematological,
             pulmonary, central nervous, cardiovascular or gastrointestinal disorders (except HIV
             infection, chronic or active Hepatitis-B-Virus or Hepatitis-C-Virus infection).

         11. Clinically significant psychiatric disorder not adequately controlled by medical
             treatment.

         12. History of coronary heart disease, myocardial infarction, angina pectoris, congestive
             heart failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high
             blood pressure, or any other heart condition under the care of a doctor.

         13. Known history of an immediate family member (father, mother, brother, or sister) who
             has had onset of ischemic heart disease before age 50 years.

         14. Ten percent or greater risk of developing a myocardial infarction or coronary death
             within the next 10 years using the National Cholesterol Education Program's risk
             assessment tool (http://hin.nhlbi.nih.gov/atpiii/calculator.asp?usertype=prof). NOTE:
             This criterion applies only to subjects 20 years of age and older.

         15. Current alcohol abuse (40 g/day for at least 6 month) and/or intravenous and/or
             intranasal drug abuse (within the past 6 months).

         16. Known allergy to MVA-BN® vaccine or any of its constituents, e.g. tris
             (hydroxymethyl)-amino methane, including known allergy to egg or aminoglycosides.

         17. History of anaphylaxis or severe allergic reaction to any vaccine.

         18. Acute disease (illness with or without a fever) at the time of enrollment.

         19. Body temperature ≥ 100.4°F (≥ 38.0°C) at the time of enrollment.

         20. Having received any vaccinations or planned vaccinations with a live vaccine within 30
             days prior to or after trial vaccination.

         21. Having received any vaccinations or planned vaccinations with a killed vaccine within
             14 days prior to or after trial vaccination.

         22. Use of immunosuppressant or immunomodulatory agents including systemic glucocorticoids
             (excluding nasal or inhaled steroids), tacrolimus, sirolimus, rapamycin,
             mycophenolate, cyclosporine, TNF-alpha blockers or antagonists, azathioprine,
             interferon, growth factors, or intravenous immunoglobulin in the 60 days prior to
             enrollment in this clinical trial.

         23. Post organ transplant subjects whether or not receiving chronic immunosuppressive
             therapy.

         24. Administration or planned administration of immunoglobulins and/or any blood products
             during a period starting from three months prior to administration of the vaccine and
             ending at last physical trial visit.

         25. Use of any investigational or non-registered drug or vaccine other than the trial
             vaccine within 30 days preceding the first dose of the trial vaccine, or planned
             administration of such a drug during the trial period.

         26. Trial personnel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edgar T Overton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health for Life Clinic Little Rock</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dupont Circle Physicians Group</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Associats of NW Florida Center for Prevention and Treatment of Infections Infectious Diseases Associates of NW FL</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rowan Tree Medical</name>
      <address>
        <city>Wilton Manors</city>
        <state>Florida</state>
        <zip>33305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Departments of Internal Medicine and Microbiology University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Clinical Trials Unit</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Puerto Rico, Inc.</name>
      <address>
        <city>San Juan</city>
        <zip>009091711</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion de Investigacion</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2014</study_first_posted>
  <results_first_submitted>February 13, 2020</results_first_submitted>
  <results_first_submitted_qc>March 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2020</results_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 18, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT02038881/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 5, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT02038881/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened and enrolled at 12 sites in the US</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1 (Standard Regimen)</title>
          <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
        </group>
        <group group_id="P2">
          <title>Group 2 (Double Dose Regimen)</title>
          <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
        </group>
        <group group_id="P3">
          <title>Group 3 (Booster Regimen)</title>
          <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>incarcerated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 (Standard Regimen)</title>
          <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
        </group>
        <group group_id="B2">
          <title>Group 2 (Double Dose Regimen)</title>
          <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
        </group>
        <group group_id="B3">
          <title>Group 3 (Booster Regimen)</title>
          <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="87"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.1" spread="7.66"/>
                    <measurement group_id="B2" value="33.1" spread="6.67"/>
                    <measurement group_id="B3" value="36.6" spread="5.43"/>
                    <measurement group_id="B4" value="35" spread="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oriental/Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian/Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With SAEs</title>
        <description>Occurrence, relationship and intensity of any serious AE (SAE)</description>
        <time_frame>within 75 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With SAEs</title>
          <description>Occurrence, relationship and intensity of any serious AE (SAE)</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE with intensity &gt;= Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE assessed as related to vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With AESIs</title>
        <description>Occurrence, relationship to the trial vaccine, and intensity of any adverse event of special interest (AESI)</description>
        <time_frame>within 75 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With AESIs</title>
          <description>Occurrence, relationship to the trial vaccine, and intensity of any adverse event of special interest (AESI)</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AESI with intensity &gt;= Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AESI assessed as related to vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Related Grade &gt;=3 Adverse Events</title>
        <description>Number of Participants with any Grade &gt;=3 Adverse Event probably, possibly, or definitely related to the study vaccine. Pooled solicited and unsolicited AEs.</description>
        <time_frame>within 29 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Related Grade &gt;=3 Adverse Events</title>
          <description>Number of Participants with any Grade &gt;=3 Adverse Event probably, possibly, or definitely related to the study vaccine. Pooled solicited and unsolicited AEs.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Unsolicited Non-serious Adverse Events: Relationship to Vaccination</title>
        <description>Occurrence of unsolicited non-serious AEs by relationship to study vaccine</description>
        <time_frame>within 29 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Unsolicited Non-serious Adverse Events: Relationship to Vaccination</title>
          <description>Occurrence of unsolicited non-serious AEs by relationship to study vaccine</description>
          <population>Full Analysis Set</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unrelated/None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unlikely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Unsolicited Non-serious Adverse Events: Intensity</title>
        <description>Occurrence of unsolicited non-serious AEs by Intensity</description>
        <time_frame>within 29 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Unsolicited Non-serious Adverse Events: Intensity</title>
          <description>Occurrence of unsolicited non-serious AEs by Intensity</description>
          <population>Full Analysis Set</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited Local Adverse Events</title>
        <description>Number of participants with solicited local AEs (redness, swelling, induration, pruritus, and pain) by intensity. Percentages based on subjects with at least one completed diary card. [Injection site erythema, injection site swelling and injection site induration--all sizes measured in diameter with max severity of: 0=0, 1 = &lt;30 mm, 2 = ≥30 - &lt;100 mm, 3 = ≥100 mm. Injection site pruritus: 0=absent, 1=mild, 2=moderate, 3=severe. Injection site pain: 0=absent, 1=painful to touch, 2=painful when limb is moved, 3=spontaneously painful/prevents normal activity.]</description>
        <time_frame>within 8 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Local Adverse Events</title>
          <description>Number of participants with solicited local AEs (redness, swelling, induration, pruritus, and pain) by intensity. Percentages based on subjects with at least one completed diary card. [Injection site erythema, injection site swelling and injection site induration--all sizes measured in diameter with max severity of: 0=0, 1 = &lt;30 mm, 2 = ≥30 - &lt;100 mm, 3 = ≥100 mm. Injection site pruritus: 0=absent, 1=mild, 2=moderate, 3=severe. Injection site pain: 0=absent, 1=painful to touch, 2=painful when limb is moved, 3=spontaneously painful/prevents normal activity.]</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection Site Pain, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pain, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pain, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Erythema, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Erythema, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Erythema, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Swelling, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Swelling, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Swelling, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Induration, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Induration, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Induration, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pruritus, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pruritus, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pruritus, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited General AEs</title>
        <description>Number of Participants with solicited systemic/general AEs (pyrexia, headache, myalgia, nausea, fatigue, and chills) by intensity. Percentages based on subjects with at least one completed diary card. [Body temperature: 0 = &lt;99.5 F (&lt;37.5 C), 1 = ≥99.5 - &lt;100.4 F (≥37.5 - &lt;38.0 C), 2= ≥100.4 - &lt;102.2 F (≥38.0 - &lt;39.0 C), 3= ≥102.2 - &lt;104.0 F (≥39.0 - &lt;40.0 C), 4= ≥ 104.0 F (≥40.0 C); pyrexia is defined as oral temperature ≥ 100.4 F (≥ 38.0 C).] [Headache, myalgia, nausea, chills and fatigue: 0 = none, 1 = mild: easily tolerated, minimal discomfort and no interference with daily activity, 2 = moderate: some interference with daily activity, 3 = severe: prevents daily activity.]</description>
        <time_frame>within 8 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited General AEs</title>
          <description>Number of Participants with solicited systemic/general AEs (pyrexia, headache, myalgia, nausea, fatigue, and chills) by intensity. Percentages based on subjects with at least one completed diary card. [Body temperature: 0 = &lt;99.5 F (&lt;37.5 C), 1 = ≥99.5 - &lt;100.4 F (≥37.5 - &lt;38.0 C), 2= ≥100.4 - &lt;102.2 F (≥38.0 - &lt;39.0 C), 3= ≥102.2 - &lt;104.0 F (≥39.0 - &lt;40.0 C), 4= ≥ 104.0 F (≥40.0 C); pyrexia is defined as oral temperature ≥ 100.4 F (≥ 38.0 C).] [Headache, myalgia, nausea, chills and fatigue: 0 = none, 1 = mild: easily tolerated, minimal discomfort and no interference with daily activity, 2 = moderate: some interference with daily activity, 3 = severe: prevents daily activity.]</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pyrexia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ T Cell Counts</title>
        <description>Mean CD4+ T-cell counts over time</description>
        <time_frame>within 15 days after each vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ T Cell Counts</title>
          <description>Mean CD4+ T-cell counts over time</description>
          <population>Full Analysis Set</population>
          <units>CD4 count (cells/µL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.9" spread="104.77"/>
                    <measurement group_id="O2" value="295.3" spread="111.10"/>
                    <measurement group_id="O3" value="349.6" spread="133.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337.4" spread="118.18"/>
                    <measurement group_id="O2" value="357.0" spread="157.87"/>
                    <measurement group_id="O3" value="335.7" spread="111.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319.1" spread="117.91"/>
                    <measurement group_id="O2" value="365.4" spread="197.04"/>
                    <measurement group_id="O3" value="345.0" spread="96.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">N/A=week 14 visit not scheduled for Group 1</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">N/A=week 14 visit not scheduled for Group 2</measurement>
                    <measurement group_id="O3" value="351.9" spread="114.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMT) Measured by Enzyme-linked Immunosorbent Assay (ELISA) at All Immunogenicity Sampling Points</title>
        <description>GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'.</description>
        <time_frame>within 64 weeks</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) Measured by Enzyme-linked Immunosorbent Assay (ELISA) at All Immunogenicity Sampling Points</title>
          <description>GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'.</description>
          <population>Per-protocol Set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.8" upper_limit="2.6"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.8" upper_limit="1.7"/>
                    <measurement group_id="O3" value="1.8" lower_limit="0.9" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="15.3" upper_limit="105.1"/>
                    <measurement group_id="O2" value="47.1" lower_limit="20.7" upper_limit="107.1"/>
                    <measurement group_id="O3" value="41.8" lower_limit="16.2" upper_limit="107.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="552.2" lower_limit="337.1" upper_limit="904.4"/>
                    <measurement group_id="O2" value="846.1" lower_limit="475.3" upper_limit="1506.1"/>
                    <measurement group_id="O3" value="726.1" lower_limit="371.3" upper_limit="1419.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 1</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 2</measurement>
                    <measurement group_id="O3" value="193.1" lower_limit="90.9" upper_limit="410.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 1</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 2</measurement>
                    <measurement group_id="O3" value="1591.2" lower_limit="1158.1" upper_limit="2186.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30/38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" lower_limit="12.2" upper_limit="98.5"/>
                    <measurement group_id="O2" value="30.8" lower_limit="11.3" upper_limit="83.5"/>
                    <measurement group_id="O3" value="143.3" lower_limit="67.6" upper_limit="303.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" lower_limit="8.4" upper_limit="75.7"/>
                    <measurement group_id="O2" value="27.5" lower_limit="9.6" upper_limit="79.2"/>
                    <measurement group_id="O3" value="116.2" lower_limit="57.9" upper_limit="233.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 1 / Group 2) at Week 4</param_type>
            <param_value>0.851</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.258</ci_lower_limit>
            <ci_upper_limit>2.800</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 1 / Group 2) at Week 6</param_type>
            <param_value>0.653</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.319</ci_lower_limit>
            <ci_upper_limit>1.333</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 1 / Group 2) at Week 30</param_type>
            <param_value>1.126</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.291</ci_lower_limit>
            <ci_upper_limit>4.352</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 1 / Group 2) at Week 56</param_type>
            <param_value>0.916</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.220</ci_lower_limit>
            <ci_upper_limit>3.819</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 3 / Group 1) at Week 4</param_type>
            <param_value>1.045</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.292</ci_lower_limit>
            <ci_upper_limit>3.741</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 3 / Group 1) at Week 6</param_type>
            <param_value>1.315</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.598</ci_lower_limit>
            <ci_upper_limit>2.892</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA GMT 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined))</title>
        <description>GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'.</description>
        <time_frame>Week 6</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 and 3 Combined</title>
            <description>Pooling of Groups 1 and 3 (same dose/regimen before booster vaccination in Group 3)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Double dose regimen</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA GMT 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined))</title>
          <description>GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'.</description>
          <population>Per-protocol Set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="644.6" lower_limit="422.7" upper_limit="983.0"/>
                    <measurement group_id="O2" value="846.1" lower_limit="475.3" upper_limit="1506.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 1+3 [pooled] / Group 2)</param_type>
            <param_value>0.762</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.385</ci_lower_limit>
            <ci_upper_limit>1.507</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA GMT 2 Weeks Following the Last Vaccination</title>
        <description>GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'.</description>
        <time_frame>Week 6 (Groups 1 and 2), Week 14 (Group 3)</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA GMT 2 Weeks Following the Last Vaccination</title>
          <description>GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'.</description>
          <population>Per-protocol Set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="552.2" lower_limit="337.1" upper_limit="904.4"/>
                    <measurement group_id="O2" value="846.1" lower_limit="475.3" upper_limit="1506.1"/>
                    <measurement group_id="O3" value="1591.2" lower_limit="1158.1" upper_limit="2186.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 1 [W6]/ Group 3 [W14)</param_type>
            <param_value>0.347</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.200</ci_lower_limit>
            <ci_upper_limit>0.603</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT ratio (Group 2 [W6]/ Group 3 [W14])</param_type>
            <param_value>0.532</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.285</ci_lower_limit>
            <ci_upper_limit>0.992</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA GMT During Follow-up</title>
        <description>GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'. Participants discontinued prior to the follow-up visits are excluded.</description>
        <time_frame>Weeks 30 and 56 (Groups 1 and 2), Weeks 38 and 64 (Group 3)</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA GMT During Follow-up</title>
          <description>GMTs based on vaccinia-specific ELISA. Titers below the detection limit are included with a value of '1'. Participants discontinued prior to the follow-up visits are excluded.</description>
          <population>Per-protocol Set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 30/38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" lower_limit="12.2" upper_limit="98.5"/>
                    <measurement group_id="O2" value="30.8" lower_limit="11.3" upper_limit="83.5"/>
                    <measurement group_id="O3" value="143.3" lower_limit="67.6" upper_limit="303.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" lower_limit="8.4" upper_limit="75.7"/>
                    <measurement group_id="O2" value="27.5" lower_limit="9.6" upper_limit="79.2"/>
                    <measurement group_id="O3" value="116.2" lower_limit="57.9" upper_limit="233.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 3 [W38]/ Group 1 [W30])</param_type>
            <param_value>4.138</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.241</ci_lower_limit>
            <ci_upper_limit>13.793</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 3 [W64]/ Group 1 [W56])</param_type>
            <param_value>4.608</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.365</ci_lower_limit>
            <ci_upper_limit>15.558</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 2 [W30]/ Group 3 [W38])</param_type>
            <param_value>0.215</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.066</ci_lower_limit>
            <ci_upper_limit>0.699</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 2 [W56]/ Group 3 [W64])</param_type>
            <param_value>0.237</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.072</ci_lower_limit>
            <ci_upper_limit>0.782</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs Measured by Plaque Reduction Neutralization Test (PRNT) at All Immunogenicity Sampling Points</title>
        <description>GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'.</description>
        <time_frame>within 64 weeks</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs Measured by Plaque Reduction Neutralization Test (PRNT) at All Immunogenicity Sampling Points</title>
          <description>GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'.</description>
          <population>Per-protocol Set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">None of the participants have titer values above the detection limit.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">None of the participants have titer values above the detection limit.</measurement>
                    <measurement group_id="O3" value="1.2" lower_limit="0.8" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="1.9" upper_limit="8.1"/>
                    <measurement group_id="O2" value="4.8" lower_limit="2.5" upper_limit="9.2"/>
                    <measurement group_id="O3" value="10.1" lower_limit="4.8" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" lower_limit="49.9" upper_limit="124.8"/>
                    <measurement group_id="O2" value="100.3" lower_limit="59.8" upper_limit="168.4"/>
                    <measurement group_id="O3" value="95.9" lower_limit="54.6" upper_limit="168.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 1</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 2</measurement>
                    <measurement group_id="O3" value="35.5" lower_limit="19.6" upper_limit="64.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 1</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 2</measurement>
                    <measurement group_id="O3" value="281.1" lower_limit="166.6" upper_limit="474.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30/38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="2.6" upper_limit="14.8"/>
                    <measurement group_id="O2" value="11.5" lower_limit="5.6" upper_limit="23.5"/>
                    <measurement group_id="O3" value="41.5" lower_limit="22.6" upper_limit="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="2.5" upper_limit="15.4"/>
                    <measurement group_id="O2" value="10.6" lower_limit="5.3" upper_limit="21.2"/>
                    <measurement group_id="O3" value="45.3" lower_limit="26.0" upper_limit="79.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 1 / Group 2) at Week 4</param_type>
            <param_value>0.823</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.333</ci_lower_limit>
            <ci_upper_limit>2.038</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 1 / Group 2) at Week 6</param_type>
            <param_value>0.787</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.410</ci_lower_limit>
            <ci_upper_limit>1.508</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 1 / Group 2) at Week 30</param_type>
            <param_value>0.535</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.187</ci_lower_limit>
            <ci_upper_limit>1.536</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 1 / Group 2) at Week 56</param_type>
            <param_value>0.590</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.203</ci_lower_limit>
            <ci_upper_limit>1.716</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 3 / Group 1) at Week 4</param_type>
            <param_value>2.557</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.972</ci_lower_limit>
            <ci_upper_limit>6.731</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 3 / Group 1) at Week 6</param_type>
            <param_value>1.215</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.612</ci_lower_limit>
            <ci_upper_limit>2.412</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PRNT GMT 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined))</title>
        <description>GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'.</description>
        <time_frame>Week 6</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 and 3 Combined</title>
            <description>Pooling of Groups 1 and 3 (same dose/regimen before booster vaccination in Group 3)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Double dose regimen</description>
          </group>
        </group_list>
        <measure>
          <title>PRNT GMT 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined))</title>
          <description>GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'.</description>
          <population>Per-protocol Set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1" lower_limit="61.3" upper_limit="126.6"/>
                    <measurement group_id="O2" value="100.3" lower_limit="59.8" upper_limit="168.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 1+3 [pooled] / Group 2)</param_type>
            <param_value>0.878</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.480</ci_lower_limit>
            <ci_upper_limit>1.606</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PRNT GMT 2 Weeks Following the Last Vaccination</title>
        <description>GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'.</description>
        <time_frame>Week 6 (Groups 1 and 2), Week 14 (Group 3)</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>PRNT GMT 2 Weeks Following the Last Vaccination</title>
          <description>GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'.</description>
          <population>Per-protocol Set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" lower_limit="49.9" upper_limit="124.8"/>
                    <measurement group_id="O2" value="100.3" lower_limit="59.8" upper_limit="168.4"/>
                    <measurement group_id="O3" value="281.1" lower_limit="166.6" upper_limit="474.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT ratio (Group 1 [W6]/ Group 3 [W14)</param_type>
            <param_value>0.281</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.146</ci_lower_limit>
            <ci_upper_limit>0.542</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT ratio (Group 2 [W6]/ Group 3 [W14])</param_type>
            <param_value>0.357</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.178</ci_lower_limit>
            <ci_upper_limit>0.718</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PRNT GMT During Follow-up</title>
        <description>GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'. Participants discontinued prior to the follow-up visits are excluded.</description>
        <time_frame>Weeks 30 and 56 (Groups 1 and 2), Weeks 38 and 64 (Group 3)</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>PRNT GMT During Follow-up</title>
          <description>GMTs based on vaccinia-specific PRNT. Titers below the detection limit are included with a value of '1'. Participants discontinued prior to the follow-up visits are excluded.</description>
          <population>Per-protocol Set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 30/38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="2.6" upper_limit="14.8"/>
                    <measurement group_id="O2" value="11.5" lower_limit="5.6" upper_limit="23.5"/>
                    <measurement group_id="O3" value="41.5" lower_limit="22.6" upper_limit="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="2.5" upper_limit="15.4"/>
                    <measurement group_id="O2" value="10.6" lower_limit="5.3" upper_limit="21.2"/>
                    <measurement group_id="O3" value="45.3" lower_limit="26.0" upper_limit="79.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 3 [W38]/ Group 1 [W30])</param_type>
            <param_value>6.727</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.493</ci_lower_limit>
            <ci_upper_limit>18.150</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 3 [W64]/ Group 1 [W56])</param_type>
            <param_value>7.275</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.693</ci_lower_limit>
            <ci_upper_limit>19.649</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 2 [W30]/ Group 3 [W38])</param_type>
            <param_value>0.278</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.115</ci_lower_limit>
            <ci_upper_limit>0.672</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group 2 [W56]/ Group 3 [W64])</param_type>
            <param_value>0.233</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.100</ci_lower_limit>
            <ci_upper_limit>0.541</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion by ELISA</title>
        <description>SC rate based on ELISA. SC is defined as the appearance of antibody titers &gt;= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>within 64 weeks</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion by ELISA</title>
          <description>SC rate based on ELISA. SC is defined as the appearance of antibody titers &gt;= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Per-protocol Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="50.9" upper_limit="91.3"/>
                    <measurement group_id="O2" value="82.6" lower_limit="61.2" upper_limit="95.0"/>
                    <measurement group_id="O3" value="69.2" lower_limit="48.2" upper_limit="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="83.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="85.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="92.3" lower_limit="74.9" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 1</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 2</measurement>
                    <measurement group_id="O3" value="84.6" lower_limit="65.1" upper_limit="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 1</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 2</measurement>
                    <measurement group_id="O3" value="100.0" lower_limit="86.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30/38</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="52.4" upper_limit="93.6"/>
                    <measurement group_id="O2" value="72.7" lower_limit="49.8" upper_limit="89.3"/>
                    <measurement group_id="O3" value="83.3" lower_limit="62.6" upper_limit="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="41.0" upper_limit="86.7"/>
                    <measurement group_id="O2" value="68.2" lower_limit="45.1" upper_limit="86.1"/>
                    <measurement group_id="O3" value="83.3" lower_limit="62.6" upper_limit="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 1 - Gr 2) at Week 4</param_type>
            <param_value>-7.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.1</ci_lower_limit>
            <ci_upper_limit>17.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 1 - Gr 2) at Week 6</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.8</ci_lower_limit>
            <ci_upper_limit>16.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 1 - Gr 2) at Week 30</param_type>
            <param_value>5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.5</ci_lower_limit>
            <ci_upper_limit>32.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 1 - Gr 2) at Week 56</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.5</ci_lower_limit>
            <ci_upper_limit>29.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 3 - Gr 1) at Week 4</param_type>
            <param_value>-5.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.8</ci_lower_limit>
            <ci_upper_limit>22.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 3 - Gr 1) at Week 6</param_type>
            <param_value>-7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.1</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion by ELISA 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined))</title>
        <description>SC rate based on ELISA. SC is defined as the appearance of antibody titers &gt;= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>Week 6</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 and 3 Combined</title>
            <description>Pooling of Groups 1 and 3 (same dose/regimen before booster vaccination in Group 3)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Double dose regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion by ELISA 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined))</title>
          <description>SC rate based on ELISA. SC is defined as the appearance of antibody titers &gt;= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Per-protocol Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="85.2" upper_limit="99.5"/>
                    <measurement group_id="O2" value="100.0" lower_limit="85.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in seroconversion rates (%)</param_type>
            <param_value>-4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.2</ci_lower_limit>
            <ci_upper_limit>11.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion by ELISA 2 Weeks Following the Last Vaccination</title>
        <description>SC rate based on ELISA. SC is defined as the appearance of antibody titers &gt;= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>Week 6 (Groups 1 and 2), Week 14 (Group 3)</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion by ELISA 2 Weeks Following the Last Vaccination</title>
          <description>SC rate based on ELISA. SC is defined as the appearance of antibody titers &gt;= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Per-protocol Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="83.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="85.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="86.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 1 [W6] - Gr 3 [W14])</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.1</ci_lower_limit>
            <ci_upper_limit>13.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 2 [W6] - Gr 3 [W14])</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.2</ci_lower_limit>
            <ci_upper_limit>13.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion by ELISA During Follow-up</title>
        <description>SC rate based on ELISA. SC is defined as the appearance of antibody titers &gt;= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>Weeks 30 and 56 (Groups 1 and 2), Weeks 38 and 64 (Group 3)</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion by ELISA During Follow-up</title>
          <description>SC rate based on ELISA. SC is defined as the appearance of antibody titers &gt;= detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Per-protocol Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 30/38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="52.4" upper_limit="93.6"/>
                    <measurement group_id="O2" value="72.7" lower_limit="49.8" upper_limit="89.3"/>
                    <measurement group_id="O3" value="83.3" lower_limit="62.6" upper_limit="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="41.0" upper_limit="86.7"/>
                    <measurement group_id="O2" value="68.2" lower_limit="45.1" upper_limit="86.1"/>
                    <measurement group_id="O3" value="83.3" lower_limit="62.6" upper_limit="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr3 [W38] - Gr1 [W30])</param_type>
            <param_value>5.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.6</ci_lower_limit>
            <ci_upper_limit>33.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr3 [W64] - Gr1 [W56])</param_type>
            <param_value>16.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.0</ci_lower_limit>
            <ci_upper_limit>44.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr2 [W30] - Gr3 [W38])</param_type>
            <param_value>-10.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.6</ci_lower_limit>
            <ci_upper_limit>14.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr2 [W56] - Gr3 [W64])</param_type>
            <param_value>-15.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.5</ci_lower_limit>
            <ci_upper_limit>10.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion by PRNT</title>
        <description>SC rate based on PRNT. SC is defined as the appearance of antibody titers &gt;= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>within 64 weeks</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion by PRNT</title>
          <description>SC rate based on PRNT. SC is defined as the appearance of antibody titers &gt;= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Per-protocol Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="36.1" upper_limit="80.9"/>
                    <measurement group_id="O2" value="69.6" lower_limit="47.1" upper_limit="86.8"/>
                    <measurement group_id="O3" value="80.8" lower_limit="60.6" upper_limit="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="83.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="85.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="96.2" lower_limit="80.4" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 1</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 2</measurement>
                    <measurement group_id="O3" value="96.2" lower_limit="80.4" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 1</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">N/A=week 12 and 14 visits not scheduled for Group 2</measurement>
                    <measurement group_id="O3" value="100.0" lower_limit="86.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30/38</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" lower_limit="46.5" upper_limit="90.3"/>
                    <measurement group_id="O2" value="81.8" lower_limit="59.7" upper_limit="94.8"/>
                    <measurement group_id="O3" value="91.7" lower_limit="73.0" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="41.0" upper_limit="86.7"/>
                    <measurement group_id="O2" value="72.7" lower_limit="49.8" upper_limit="89.3"/>
                    <measurement group_id="O3" value="95.8" lower_limit="78.9" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 1 - Gr 2) at Week 4</param_type>
            <param_value>-9.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.4</ci_lower_limit>
            <ci_upper_limit>20.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 1 - Gr 2) at Week 6</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.8</ci_lower_limit>
            <ci_upper_limit>16.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 1 - Gr 2) at Week 30</param_type>
            <param_value>-9.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.4</ci_lower_limit>
            <ci_upper_limit>17.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 1 - Gr 2) at Week 56</param_type>
            <param_value>-6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.6</ci_lower_limit>
            <ci_upper_limit>23.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 3 - Gr 1) at Week 4</param_type>
            <param_value>20.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.7</ci_lower_limit>
            <ci_upper_limit>47.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 3 - Gr 1) at Week 6</param_type>
            <param_value>-3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.5</ci_lower_limit>
            <ci_upper_limit>13.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion by PRNT 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined))</title>
        <description>SC rate based on PRNT. SC is defined as the appearance of antibody titers &gt;= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>Week 6</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 and 3 Combined</title>
            <description>Pooling of Groups 1 and 3 (same dose/regimen before booster vaccination in Group 3)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Double dose regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion by PRNT 2 Weeks Following the Second Vaccination (Group 2 Compared to Group 1 and Group 3 (Combined))</title>
          <description>SC rate based on PRNT. SC is defined as the appearance of antibody titers &gt;= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Per-protocol Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="88.5" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="85.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in seroconversion rates (%)</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.0</ci_lower_limit>
            <ci_upper_limit>13.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion by PRNT 2 Weeks Following the Last Vaccination</title>
        <description>SC rate based on PRNT. SC is defined as the appearance of antibody titers &gt;= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>Week 6 (Groups 1 and 2), Week 14 (Group 3)</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion by PRNT 2 Weeks Following the Last Vaccination</title>
          <description>SC rate based on PRNT. SC is defined as the appearance of antibody titers &gt;= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Per-protocol Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="83.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="85.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="86.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 1 [W6] - Gr 3 [W14])</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.1</ci_lower_limit>
            <ci_upper_limit>13.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr 2 [W6] - Gr 3 [W14])</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.2</ci_lower_limit>
            <ci_upper_limit>13.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion by PRNT During Follow-up</title>
        <description>SC rate based on PRNT. SC is defined as the appearance of antibody titers &gt;= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>Weeks 30 and 56 (Groups 1 and 2), Weeks 38 and 64 (Group 3)</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Standard Regimen)</title>
            <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Double Dose Regimen)</title>
            <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (Booster Regimen)</title>
            <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion by PRNT During Follow-up</title>
          <description>SC rate based on PRNT. SC is defined as the appearance of antibody titers &gt;= detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Per-protocol Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 30/38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" lower_limit="46.5" upper_limit="90.3"/>
                    <measurement group_id="O2" value="81.8" lower_limit="59.7" upper_limit="94.8"/>
                    <measurement group_id="O3" value="91.7" lower_limit="73.0" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56/64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="41.0" upper_limit="86.7"/>
                    <measurement group_id="O2" value="72.7" lower_limit="49.8" upper_limit="89.3"/>
                    <measurement group_id="O3" value="95.8" lower_limit="78.9" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr3 [W38] - Gr1 [W30])</param_type>
            <param_value>19.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>45.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr3 [W64] - Gr1 [W56])</param_type>
            <param_value>29.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.8</ci_lower_limit>
            <ci_upper_limit>55.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr2 [W30] - Gr3 [W38])</param_type>
            <param_value>-9.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.0</ci_lower_limit>
            <ci_upper_limit>11.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diff in SC rate (Gr2 [W56] - Gr3 [W64])</param_type>
            <param_value>-23.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.7</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>within 75 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (Standard Regimen)</title>
          <description>One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
        </group>
        <group group_id="E2">
          <title>Group 2 (Double Dose Regimen)</title>
          <description>Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
        </group>
        <group group_id="E3">
          <title>Group 3 (Booster Regimen)</title>
          <description>One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
IMVAMUNE®: 0.5 ml Modified Vaccinia Ankara Strain – Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Human bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Program Lead, Clinical Operations</name_or_title>
      <organization>Bavarian Nordic A/S</organization>
      <phone>+45 3326 ext 8383</phone>
      <email>info@bavarian-nordic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

